Author Archive: Cartier Esham

Cartier Esham

Cartier Esham serves as Executive Vice President for Emerging Companies at the Biotechnology Industry Organization (BIO). In this role, Dr. Esham manages and directs BIO’s policy development, advocacy, research and educational initiatives for BIO’s emerging companies, which comprise approximately 90percent of BIO’s membership.

Latest Posts

Conference on Clinical Research for Rare Diseases on November 3rd


BIO members may be interested in the upcoming Conference on Clinical Research for Rare Diseases, hosted by the Rare Diseases Clinical Research Network.  The Rare Diseases Clinical Research Network is an initiative of the Office of Rare Diseases Research, NCATS, funded through a collaboration between NCATS and the NIH.  The conference will be held on November 3, 2016 at the Washington Marriott Wardman Park. There are more than 6,800 diseases classified as “rare” (defined as Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Applauds House Passage of the Fostering Innovation Act

scientist, lab

The House of Representatives has overwhelmingly passed the Fostering Innovation Act (H.R. 4139), a key capital markets priority for BIO. The bipartisan legislation was introduced by Reps. Kyrsten Sinema (D-AZ) and Michael Fitzpatrick (R-PA). The JOBS Act provides emerging growth companies (EGCs) with a five-year exemption from Section 404(b) of Sarbanes-Oxley (SOX), which requires a costly external attestation of a company’s internal financial controls. The Fostering Innovation Act would extend the JOBS Act’s SOX 404(b) Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Exclusive FDA Survey Webinar


BIO is conducting an exciting new survey designed to measure FDA/Sponsor Interactions During Drug Development.  We are excited to announce an exclusive webinar for survey participants only to reveal the preliminary results of the study.  Participants are invited to attend this webinar to gain exclusive access to survey insights and hear analysis of the survey data from regulatory experts, including FDA staff. This exciting webinar opportunity is scheduled for Wednesday, January 28 at 1:00 pm Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Roadblocks and Red Tape Block Search for Cures

scientist, lab

Since its passage more than two years ago, the JOBS Act has spurred more than 110 biotech IPOs. And now the SEC is in the process of finalizing another important piece of the law that could further encourage biotech capital formation. The JOBS Act directs the SEC to raise the offering ceiling under Regulation A – a securities law exemption that allows companies to raise public capital with a reduced reporting burden – from $5 Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Biotech Stocks: Perspective in a Bull Market

biotech companies

Investors are increasingly interested in biotechnology based on scientific breakthroughs, an improved regulatory environment, strong earnings growth from large companies, and a more mature industry. Recent advancements in biotechnology are revolutionizing treatments and cures for many illnesses, creating new value for the healthcare system. In 2013, our understanding of how therapeutics can be used to harness the immune system to destroy cancer cells exploded with many companies reporting solid data in human testing. In 2014, Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , ,